KOSDAQBiotech & Pharma314130

Genome&Company

₩2,995▲ 2.57%2026-11-18 close
Market Cap
₩161B
Turnover
₩400M
Volume
150K
Shares out.
53.8M
PER
—
PBR
—
EPS
-₩850
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Genome&Company: licensing milestones versus a persistent operating loss

Genome&Company is leaning on out-licensing of first-in-class candidates and a growing cosmetics business, yet its filed results show operating losses in every year from 2022 to 2025 and in each of the last five quarters.

  1. 1

    The operating loss widened to KRW 29.2 billion in 2025 from KRW 24.2 billion in 2024. The company has recorded losses for four consecutive years from 2022 to 2025, and total equity at the end of 2025 was KRW 114.6 billion.

  2. 2

    Press reports put consumer-business sales at KRW 8.1 billion, or 68%, of KRW 12.0 billion in consolidated first-half 2026 revenue. Licensing royalty income fell to zero in 2025, so revenue has tilted toward cosmetics.

  3. 3

    Third-quarter 2026 revenue rose to KRW 7.24 billion, up for two consecutive quarters, while the operating loss was KRW 7.45 billion in the same quarter. Revenue recovery and loss reduction have not yet appeared together.

  4. 4

    The company raised KRW 30.0 billion in March 2026 through convertible bonds (KRW 27.0 billion) and convertible preferred shares (KRW 3.0 billion), followed by a KRW 7.0 billion third-party share issuance in April, so funding and dilution are advancing together.

  5. 5

    At a June 2026 press briefing, the company set a target of at least one licensing deal per year, with one deal aimed for the second half of 2026 and another in 2027, making deal execution the next checkpoint.

02

Business structure

Genome&Company uses its in-house GNOCLE platform to identify novel targets and license candidates to global pharma companies, often at the preclinical stage.

Its out-licensing record includes Debio 0633, licensed to Switzerland-based Debiopharm in May 2024, and the immuno-oncology candidate EP0089 (GENA-104), licensed to UK-based Ellipses Pharma in February 2025.

Its proprietary pipeline comprises GENA-104 ADC, which targets CNTN4; GENA-120, which targets ITGB4; the bispecific ADC GENB-120; and GENC-116, a small molecule aimed at NUAK1.

The consumer business centers on the microbiome cosmetics brand UIQ, which the company says runs five lines with more than 40 products and has reached 28 countries, alongside a health supplement and cosmetic ingredient supply.

Per a Sisajournal-e report, consumer-business sales were KRW 8.1 billion, or 68%, of KRW 12.0 billion in consolidated first-half 2026 revenue, while licensing revenue has not been booked since KRW 7.1 billion in 2024.

Press reports also say the company acquired a 64.46% stake in the distributor Allbloom for KRW 5.0 billion through a wholly owned subsidiary. That distributor's 2025 revenue was KRW 23.01 billion, up 29.6%, but its gross margin fell from 25.2% to 19.9%.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.6B-₩8.1B−123.4%
2025Q4₩5.9B-₩7B−119.8%
2026Q1₩5.8B-₩6.1B−105.4%
2026Q2₩6.3B-₩8B−127.5%
2026Q3₩7.2B-₩7.5B−103.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩14.1B-₩57.5B-₩51.8B−408.3%−53.3%14.9%
2023₩14.3B-₩55.1B-₩47.5B−385.4%−76.0%42.8%
2024₩27.7B-₩24.2B-₩20.1B−87.2%−41.6%48.7%
2025₩24.6B-₩29.2B-₩6.4B−118.9%−6.1%26.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Based on filed results, annual revenue was KRW 14.1 billion in 2022, KRW 14.3 billion in 2023 (up 1.5% year on year), KRW 27.7 billion in 2024 (up 94.1%), and KRW 24.6 billion in 2025 (down 11.4%). 2024 was the largest year in the 2022 to 2025 period and 2022 the smallest.

The 2024 jump reflected KRW 7.1 billion of licensing royalty income, which fell to zero in 2025 and weighed on revenue. Press reports cite the company attributing the 2025 decline to lower CDMO and consumer sales.

Operating loss was KRW 57.5 billion in 2022, KRW 55.1 billion in 2023, KRW 24.2 billion in 2024, and KRW 29.2 billion in 2025. The operating margin moved from -408.3% in 2022 to -87.2% in 2024 and then deteriorated to -118.9% in 2025.

The company explained the 2025 widening as a base effect from one-off revenue booked on a licensing agreement in the prior year.

Net loss attributable to controlling shareholders narrowed from KRW 51.8 billion in 2022 to KRW 6.43 billion in 2025, while the net loss including non-controlling interests was KRW 7.69 billion in 2025.

The debt ratio fell from 48.7% in 2024 to 26.6% in 2025, and operating cash flow was negative in every year from 2022 to 2025, at -KRW 18.4 billion in 2025.

On a quarterly basis, the company posted a controlling-shareholder net profit of KRW 14.6 billion in Q4 2025 after turning positive, but then recorded net losses of KRW 6.35 billion in Q1 2026, KRW 42.1 billion in Q2 2026 and KRW 8.2 billion in Q3 2026.

Operating losses over the same quarters were KRW 6.1 billion, KRW 7.97 billion and KRW 7.45 billion, so the Q2 2026 net loss deserves a separate reading from operating performance. The combined controlling-shareholder net loss for the last four quarters is KRW 42 billion.

05

Industry analysis

Antibody-drug conjugates (ADCs) are an area of strong licensing demand as global big pharma companies face patent expiries and look for growth drivers.

At a June 9, 2026 press briefing, CEO Hong Yu-seok said an analysis of 104 drugs launched since 2010 found that second and third drugs in a class reached commercial success only 51% of the time, even when they were the most effective. That is the company's own analysis and has not been independently verified.

The company also argued that global ADC deal flow has shifted since 2024 from validated targets toward novel targets. That view supports its strategy of licensing candidates early, at the preclinical stage.

Industry commentary, however, flags continuing uncertainty about the follow-on development of preclinically licensed assets. EP0089, for example, reportedly carried no upfront payment at signing, which raised questions about later development.

On the cosmetics side, one industry outlook projects the microbiome market to grow from USD 0.27 billion in 2023 to USD 1.37 billion in 2029. The company frames the cosmeceutical market, which combines cosmetic and pharmaceutical features, as the backdrop for UIQ's expansion.

In competition, domestic ADC platform companies such as LigaChem Biosciences compete for the same licensing partners. Genome&Company's strength is its novel-target discovery platform, but its commercial revenue base is still small relative to larger Korean biopharma peers.

06

Outlook

The company has set a target of licensing at least one novel-target candidate per year. At the June 2026 briefing, CEO Hong Yu-seok said the goal is one deal in the second half of 2026 and one in 2027, and it also targets licensing clinical-stage candidates from 2028.

Debio 0633, licensed to Debiopharm, is in preclinical development led by the partner, and the IND submission is reportedly targeted for late 2027 to early 2028.

EP0089 (GENA-104), licensed to Ellipses Pharma, is preparing a Phase 1/2a trial designed for a total of about 190 patients across Korea, Australia, the UK and the United States.

The company's proprietary GENA-104 ADC and GENA-120 remain in nonclinical studies, and it is holding partnering meetings for further licensing. For UIQ, the company presented IR targets of KRW 20.0 billion in 2026 and KRW 40.0 billion in 2027.

These are management targets, and they would require growth well above the KRW 12.04 billion reported for 2025. The operating funds raised in April 2026 are earmarked for overseas expansion and marketing of cosmetics.

After the share price weakened in September 2026, the company said there had been no special change in its fundamentals or business progress and that it was discussing meetings with institutional investors and brokerage events.

The next checkpoints are whether the targeted second-half 2026 deal is signed and how operating losses trend in the 2026 annual report.

07

Valuation

PER
—
PBR
—
ROE
-55.9%
EPS
-₩850
BPS
—
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, a price-to-earnings ratio on earnings cannot be calculated, so multiples based on profit do not offer a direct comparison of current levels. The company pays no dividend, so its dividend yield sits below the sector average.

Total equity at the end of 2025 was KRW 114.6 billion, of which KRW 105.8 billion belonged to controlling shareholders, and total liabilities were KRW 30.4 billion, with the debt ratio falling to 26.6% from 48.7% in 2024.

Market capitalization is above the book value of shareholders' equity, which means the stock trades at a premium to net asset value. Over several years, the controlling-shareholder net loss narrowed from KRW 51.8 billion in 2022 to KRW 6.43 billion in 2025, a move toward earnings recovery in direction.

Quarterly results in 2026, however, have again shown net losses, so the trend is mixed. The company says that research and development results are the basis for a revaluation. For that reason, valuation reading depends more on whether licensing deals close and how losses trend than on earnings multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Licensed pipeline moving toward the clinic

EP0089 (GENA-104), licensed to Ellipses Pharma, is preparing a Phase 1/2a trial designed for about 190 patients across four countries. The company said it completed supply of clinical-trial drug substance and received payment in April 2026. Debio 0633 at Debiopharm is also in ongoing preclinical development, which bulls cite as a positive.

Growing consumer-revenue share

Press reports say consumer-business sales made up more than half of consolidated first-half 2026 revenue. UIQ has entered 28 countries and is stocked in major domestic retail channels and in Japan. The company has presented targets of KRW 20.0 billion for 2026 and KRW 40.0 billion for 2027.

Two quarters of revenue growth and new funding

Revenue rose in Q2 and Q3 2026, reaching KRW 7.24 billion in Q3 and up 10.4% from a year earlier. The company raised KRW 30.0 billion in March 2026 through convertible bonds and preferred shares, and added a KRW 7.0 billion share issuance in April. It says the proceeds will fund novel-target ADC development and licensing efforts.

09

Bear factors

Operating losses persist and widened in 2025

Operating losses have been recorded for four consecutive years from 2022 to 2025, and the 2025 loss of KRW 29.2 billion was larger than the KRW 24.2 billion in 2024. Operating losses continued in each quarter from Q1 to Q3 2026, at KRW 6.1 billion, KRW 7.97 billion and KRW 7.45 billion. Continued quarterly operating losses have also accumulated into net losses over the last four quarters.

Licensing revenue gap and revenue volatility

Press reports say licensing royalty income fell from KRW 7.1 billion in 2024 to zero in 2025 and was not booked in the first half of 2026. Revenue fell 11.4% to KRW 24.6 billion in 2025. The company attributes the drop to a base effect from one-off revenue recognized on the prior year's licensing agreement.

Cash decline and dilution overhang

Press reports cite cash and equivalents falling from KRW 65.6 billion to KRW 15.6 billion. Fundraising in 2026 has included two equity issues and one convertible bond, and analysts note that convertible bonds could weigh on the shares if converted into a sales overhang. In September 2026, the company said there was no special change in fundamentals after the share price fell.

10

Risk factors

Clinical and licensing execution risk

Many core assets are at preclinical or early clinical stages, so trial outcomes are uncertain. EP0089 reportedly carried no upfront payment at signing, which raised questions about follow-on development. If the target of at least one licensing deal per year slips, the revenue gap and loss pattern would continue.

Funding and dilution risk

The company raised KRW 30.0 billion through CB and CPS in March 2026 and KRW 7.0 billion in April, but further funding may be needed while operating losses continue. The April share issuance was expected to add about 2.33% to shares outstanding. Conversion of the bonds would dilute existing holders and add potential selling pressure.

Subsidiary acquisition and distribution margin risk

The company acquired a 64.46% stake in the distributor Allbloom for KRW 5.0 billion, but that distributor's gross margin fell from 25.2% to 19.9%. The company has said there are no current plans for additional investment in the business. As UIQ expands through the U.S. offline channel, managing distribution profitability remains a challenge.

11

What to watch next

  1. By December 31, 2026

    Whether the licensing deal the company targeted for the second half of 2026 is signed. This is the first test of its annual one-deal target.

  2. By March 31, 2027

    Filing of the 2026 annual report. It will confirm full-year 2026 revenue and operating loss, including Q4, on a filed basis.

  3. Mid-August 2027

    Filing of the 2027 half-year report. It is the point to check progress on management's KRW 40.0 billion UIQ target for 2027 and whether operating losses narrow.

  4. Late 2027 to early 2028

    The targeted IND submission period for Debio 0633 at Debiopharm. It indicates whether the preclinically licensed asset moves into the clinic.

12

Overall view

Genome&Company is building its strategy around novel-target ADC licensing, and the clinical entry of EP0089 and the ongoing preclinical work on Debio 0633 are documented facts. The cosmetics business has broadened the revenue base, accounting for 68% of first-half 2026 revenue according to press reports.

On the other side, operating losses have been recorded in four consecutive years from 2022 to 2025 and continued in every quarter from Q1 to Q3 2026. The combined controlling-shareholder net loss over the last four quarters is KRW 42 billion, and repeated fundraising keeps dilution a live issue.

Strengths include pipeline progress and consumer growth, while weaknesses include persistent losses, the licensing revenue gap and dilution.

The next checkpoints are whether the targeted second-half 2026 deal closes, how operating losses trend in the 2026 annual report, and UIQ's revenue path in the 2027 half-year report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. m.news.nate.com
  2. sisajournal-e.com
  3. comp.fnguide.com
  4. biotimes.co.kr
  5. bloter.net
  6. paxetv.com
  7. bloter.net
  8. sisajournal-e.com
  9. businessreport.kr
  10. m.news.nate.com
  11. m.news.nate.com
  12. m.news.nate.com
  13. news.nate.com
  14. m.news.nate.com
  15. m.news.nate.com
  16. biz.heraldcorp.com
  17. m.news.nate.com
  18. newsis.com

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis